This page shows the latest RTS,S news and features for those working in and with pharma, biotech and healthcare.
A recombinant malaria vaccine called Mosquirix (RTS, S/AS01) – developed by GlaxoSmithKline – was given a positive ‘scientific opinion’ by the EMA in 2015 after three decades of research, but is acknowledged
One of the greatest challenges for patients with P vivax malaria is preventing relapses," said GSK's president of R&D Patrick Vallance. ... GSK is also developing a four-dose vaccine for malaria - RTS, S/AS01 - that has shown 31-56% protective efficacy
Funding has now been secured for vaccination programmes using GlaxoSmithKline's malaria vaccine RTS, S, with the people due to receive the shots in 2018. ... RTS, S, acts against Plasmodium falciparum, the most deadly malaria parasite globally and the
The vaccine is based on inactivated Plasmodium falciparum sporozoites, a key stage in the parasite's life cycle. ... Mosquirix (formerly known as RTS, S) also targets P. falciparum - the most virulent form of malaria which affects 214m people a year and
Formerly known as RTS, S/ASO1, Mosquirix (Plasmodium falciparum and hepatitis B vaccine) was assessed under EMA rules that allow it to assess the quality, safety and efficacy of a medicine ... The CHMP and GSK's biologics unit agreed measures to
GSK's work on a malaria vaccine is a good example of this. ... The company's RTS, S vaccine, filed for regulatory approval in Europe last year, is designed to protect against Plasmodium falciparum, the most dangerous of the mosquito-borne malaria
More from news
Approximately 2 fully matching, plus 14 partially matching documents found.
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...